Low-dose interleukin 2 to reverse alopecia areata

JAMA Dermatology

Volumn 150, Issue 7, 2014, Pages 696-697

  Hordinsky, Maria ^a   Kaplan, Daniel H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; PREDNISONE; RECOMBINANT INTERLEUKIN 2; RUXOLITINIB;

ALOPECIA AREATA; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EDITORIAL; HAIR LOSS; HUMAN; LIGAND BINDING; LOW DRUG DOSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; UNITED STATES;

ALOPECIA AREATA; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 84904109950     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.510     Document Type: Editorial

References (15)

1. DeethsMJ, Endrizzi BT, Irvin ML, Steiner LP, Ericson ME, Hordinsky MK. Phenotypic analysis of T-cells in extensive alopecia areata scalp suggests partial tolerance. J Invest Dermatol. 2006;126(2):366-373. (Pubitemid 43323172)
2. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117(8):2019-2027. (Pubitemid 47219540)
3. Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata [published onlineMay 28, 2014]. JAMA Dermatol. doi:10.1001/jamadermatol.2014.504.
4. + regulatory T cells in alopecia areata. J Dermatol Sci. 2013;70(2):141-143.
5. Valsecchi R, Imberti G, Martino D, Cainelli T. Alopecia areata and interleukin-2 receptor. Dermatology. 1992;184(2):126-128.
6. McElwee KJ, Freyschmidt-Paul P, Hoffmann R, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124(5):947-957. (Pubitemid 40629095)
7. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13-25.
8. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067-2077.
9. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-2066.
10. Proleukin (aldesleukin) [package insert]. San Diego, CA: Prometheus Laboratories Inc; 2012.
11. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008;(2):CD004413.
12. Olsen E, Hordinsky M, McDonald-Hull S, et al; National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines. J Am Acad Dermatol. 1999;40(2, pt 1):242-246. (Pubitemid 29072802)
13. Olsen EA, Hordinsky MK, Price VH, et al; National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines, part II. J Am Acad Dermatol. 2004;51(3):440-447.
14. Waldmann TA. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Investig Dermatol Symp Proc. 2013;16(1):S28-S30.
15. Hoffmann R,Wenzel E, Huth A, et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol. 1994; 103(4):530-533. (Pubitemid 24314840)